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Abstract
Background: Long before Alzheimer’s disease was established as the leading cause of dementia in old age,
cerebrovascular lesions were known to cause cognitive deterioration and associated disability. Since the middle of
the last century, different diagnostic concepts for vascular dementia and related syndromes were put forward, yet
no widely accepted diagnostic consensus exists to date.
Discussion: Several international efforts, reviewed herein, are ongoing to define cognitive impairment due to
cerebrovascular disease in its different stages and subtypes. The role of biomarkers is also being discussed,
including cerebrospinal fluid proteins, structural and functional brain imaging, and genetic markers. The influence of
risk factors, such as diet, exercise and different comorbidities, is emphasised by population-based research, and
lifestyle changes are considered for the treatment and prevention of dementia.
Conclusion: To improve the diagnosis and management of vascular cognitive impairment, further progress has to
be made in understanding the relevant pathomechanisms, including shared mechanisms with Alzheimer’s disease;
bringing together fragmented research initiatives in coordinated international programs; testing if known risk
factors are modifiable in prospective interventional studies; and defining the pre-dementia and pre-clinical stages in
line with the concept of mild cognitive impairment due to Alzheimer’s disease.
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Background
The current paper presents the consensus of the Diag-
nostic Criteria Working Group of the 9th International
Congress on Vascular Dementia, held on October 16–18,
2015 in Ljubljana, Slovenia. The concept that late-life de-
mentia can occur in the context of cerebrovascular disease
has been known since the nineteenth century [1, 2], and
up until the 1960s, cerebral arteriosclerosis as well as
widespread white matter lesions in patients with long-
standing hypertension were seen as the main cause of
dementia in older individuals [1]. This view was challenged
by Blessed et al. [3] and others, who suggested that
Alzheimer’s disease (AD) neuropathology is the landmark
neuropathological feature in the majority of age-related de-
mentia cases. This paradigm shift led to the development
of the concept of multi-infarct dementia (e.g. dementia
following multiple brain infracts), which subsequently was
used to define vascular dementia (VaD) in several inter-
national classification systems such as the Diagnostic and
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Statistical Manual of Mental Disorders 4th edition (DSM-
IV) and the International Classification of Diseases and Re-
lated Health Problems, 10th edition (ICD-10). However,
subsequent studies suggested that the majority of VaD
cases were caused by subcortical cerebrovascular changes,
rather than by large cortical infarcts [3]. As a result of these
conflicting views, different sets of criteria for VaD were de-
veloped, including the National Institute of Neurological
Disorders and Stroke – Association Internationale pour la
Recherche et l’Enseignement en Neurosciences (NINDS-
AIREN) [4] and the State of California Alzheimer’s Disease
Diagnostic and Treatment Centers criteria [4], as well as
criteria for specific subtypes such as subcortical VaD [5].
Parallel to similar developments in the AD field, it was
recognised that cerebrovascular disease frequently co-
occurs with other pathological changes in the majority of
patients over the age of 75 [6], which is the age group
when over 70 % of dementia cases occur [7]. Simultan-
eously, there was controversy regarding the use of the term
dementia, which became synonymous with the concept of
AD dementia, requiring prominent memory deficits in
addition to impairment in at least one other cognitive do-
main. Nevertheless, this pattern of cognitive decline is not
necessarily applicable in patients with VaD [8]. Further-
more, the need for inclusion of pre-dementia changes
within a broader nosological concept similar to mild cogni-
tive impairment due to AD was also acknowledged. Based
on these considerations, the term ‘vascular cognitive im-
pairment’ (VCI) was proposed [9], which accounts for the
heterogeneous nature (and degrees) of cognitive deficits re-
lated to prominent cerebrovascular pathologies. Vascular
mild cognitive impairment [6] or vascular cognitive impair-
ment, no dementia [7] were terms proposed to categorise
the early clinical stages. However, despite VCI being clearly
a step in the right direction, it has not been widely adopted
and parallel classification systems are still being employed.
Validated clinical diagnostic criteria are important to
identify suitable subjects for clinical trials in order to de-
velop new drugs for VCI. Their relevance increases fur-
ther if treatment strategies are to be developed that
target specific pathogenic cerebrovascular mechanisms
leading to VCI [10]. Furthermore, lifestyle interventions
and other non-pharmacological approaches can only be
developed if the target populations are clearly defined
[8]. Current efforts towards a consensus on diagnostic
criteria and guidelines to account for the heterogeneous
nature of VCI, such as the recent International Society
for Vascular Behavioural and Cognitive Disorders state-
ment [11], must be encouraged. However, despite consid-
erable recent advances, there are significant gaps in our
understanding of the neurobiological mechanisms under-
pinning the various dementia forms [12]. Further research
is therefore required before definitive criteria and guide-
lines can be formulated. Additionally, the success of such
criteria will ultimately depend on a robust pathological
and clinical validation and the support of the international
research community.
The present paper summarises recent major develop-
ments in relation to the clinical diagnosis of VCI. We dis-
cuss how this entity is handled in the new DSM-V criteria,
how our knowledge about the relevant neuro-pathological
changes impacts on the concepts surrounding this diagno-
sis, and what role fluid and neuroimaging biomarkers play.
Further, we briefly summarise the current knowledge about
risk factors and how they should be addressed in the con-
text of the clinical diagnostic process. Finally, rare genetic
causes of VCI/VaD are discussed and recommendations
are provided in relation to the most relevant next steps.
Vascular cognitive impairment in DSM-V
The fifth edition of DSM, published in 2013 by the
American Psychiatric Association, introduced major
changes to the chapter referred to in DSM-IV as ‘Dementia,
delirium, amnestic, and other cognitive disorders’ [13]. One
such change concerns the used nomenclature; the chapter
being referred to as ‘Neurocognitive Disorders’ recom-
mends replacing the term dementia with that of ‘major
neurocognitive disorder’ (NCD). Two reasons are stated for
this change, firstly, dementia is wrongly attributed only to
older populations, while it can appear in young adults (e.g.
in cases of traumatic brain injury or HIV infection), and,
secondly, NCD is a broader definition – individuals with
substantial decline in a single domain can receive this diag-
nosis as opposed to the definition of dementia, which re-
quires a decline in at least two cognitive domains (memory
and another domain) [14]. Another substantial change con-
cerns the inclusion of a less severe level of cognitive impair-
ment named mild NCD, which, in DSM-IV, was subsumed
under cognitive disorder not otherwise specified. This
addition is in line with the current trends in terms of the
optimal therapeutic intervention in the very early or pre-
symptomatic stages of at-risk individuals for dementia.
However, it may also have wide economic and public health
implications, adding millions of potential new drug con-
sumers, worldwide [15].
DSM-V also attempts to minimise the use of the ‘not
otherwise specified’ category, and stresses the need to
identify the presumed underlying cause of the syndrome.
Thus, the first step in the diagnostic process is to differ-
entiate between normal neurocognitive function and
mild and major NCD, followed by a second step to as-
sign an aetiological category such as Alzheimer’s NCD,
vascular NCD or dementia with Lewy bodies (DLB)
NCD. In distinguishing among etiological subtypes,
additional diagnostic markers are required, such as
neuroimaging studies (magnetic resonance imaging (MRI)
and positron emission tomography) and other biomarkers.
DSM-V evolved from text descriptions of NCD to
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‘operationalised’ criteria, so that vascular and other non-
AD forms of NCD can now be specifically diagnosed.
Retaining the diagnosis of major or mild vascular
NCD implies that cerebrovascular disease is the dominant
(if not exclusive) pathology leading to cognitive deficits.
DSM-V suggests that such a link is established by deter-
mining that either the onset of cognitive deficits is tem-
porally related to one or more cerebrovascular events or
that evidence of cognitive decline is prominent in complex
attention processes (including processing speed) and
frontal-executive function. Furthermore, there should be
evidence of the presence of cerebrovascular disease from
the history, physical examination and/or neuroimaging
to account for the neurocognitive deficits. Finally, it is
required that the clinical manifestations are not better
explained by any other brain or systemic disorder. In
situations where the above criteria are not fully met,
DSM-V proposes to use the term of ‘possible’ or ‘probable’
vascular NCD.
Whilst the new multi-dimensional approach, integrat-
ing early clinical stages and operationalising aetiological
categories, has been well received, the use of positive
biomarker data has not been widely adopted in clinical
practice. Current diagnostic criteria do not include
quantifiable measures for core pathological changes such
as degree of small vessel disease (SVD) and many neuro-
imaging standards for research use have yet to be vali-
dated for clinical applications [10]. Furthermore, the
lack of a gold standard for measuring processing speed
and executive function hampers the standardised assess-
ment of relevant neurocognitive deficits. The diagnosis
of VCI in most clinical settings worldwide still relies
on traditional descriptive phenomenology (clinical signs
and symptoms) and on the exclusion of other possible
aetiologies [16]. It is expected that these criteria will be
further updated as new knowledge becomes available, both
in the areas of neurocognitive testing and biomarkers.
Neuropathology: vascular dementia versus
dementia with mixed pathologies
It has to be emphasised that the neuropathological
diagnosis of VaD remains challenging in the absence
of commonly accepted neuropathological criteria.Three
main diseases of cerebral blood vessels can contribute to
vascular dementia, namely atherosclerosis (AS; large- to
medium-sized arteries), SVD (small arteries and arterioles)
and cerebral amyloid angiopathy (CAA; arteries, capillaries
and rarely veins). AS, SVD and CAA can cause different
types of cerebrovascular lesions, including brain infarcts,
white matter lesions and cerebral haemorrhages (Fig. 1).
Large infarcts can be caused by thrombotic (AS) or
thromboembolic (AS, extracranial AS, cardiogenic) occlu-
sion of the vessel’s lumen. Lacunar infarcts are frequently
caused by SVD-related vessel occlusion and microinfarcts
are often related to SVD (white matter) and CAA (cortex).
Based on the pattern of cerebrovascular lesions, three types
of dementias associated with cerebrovascular disease may
be distinguished, namely multi-infarct dementia, strategic
infarct dementia and subcortical vascular encephalopathy
(Binswanger’s disease).
In post mortem studies, the prevalence of pure VaD is
very low; in a recently reported large series of 6205 par-
ticipants, only 124 cases (1.9 %) showed cerebrovascular
disease as the only morphologic substrate for clinical de-
mentia, compared to > 15 % reported in clinical studies
[17]. This discrepancy may be related to the widely held
assumption that white matter hyperintensities on MRI
are invariably associated with SVD, while recent studies
suggest that these are usually associated with cortical
neurodegenerative pathology in AD [18] and may also
be associated with increased cerebral amyloid load [19].
However, limited cerebrovascular disease is often found
in brains of elderly individuals with and without demen-
tia and it is becoming increasingly clear that the ageing
brain is characterised by the presence of multiple path-
ologies rather than the characteristic neuropathological
features of one single neurodegenerative disease only. For
instance, limited Lewy body pathology is seen in over 40 %
of AD patients and DLB virtually always shows limited AD
pathology [20], whilst a TDP-43 pathology has been dem-
onstrated in over 50 % of AD cases, having a rather distinct
topographical spreading pattern affecting the clinical pres-
entation [20]. Nevertheless, the examples above should not
be interpreted as ‘mixed dementia’ cases, where the pres-
ence of two distinct neurodegenerative diseases fulfilling all
neuropathological criteria for each disease (e.g. AD and
DLB) must be present [21]. Therefore, AD associated to
limited cerebrovascular pathology should not be referred to
as mixed dementia. However, we should be aware that even
in cases that both clinically and neuropathologically fulfil
the criteria for a single dementing disease, the presence of
additional pathologies is likely. While the extent and sever-
ity of such additional neuropathological lesions is not suffi-
cient to cause dementia, they may influence clinical
symptoms and contribute to the pathogenesis of dementia,
but their respective impact remains to be elucidated.
Risk factors and epidemiology
An important cornerstone in understanding dementia
and in developing preventive and interventional strategies
is to first unravel the risk factors of disease, especially
those that are potentially modifiable. Therefore, herein, we
will consider lifestyle and environmental factors and not
dwell into genetic risk factors. Interestingly, although
AD and VaD, as well as their pre-dementia counterparts
mild cognitive impairment due to AD and vascular mild
cognitive impairment, are still considered distinct entities,
their risk factor profiles overlap substantially. Several large
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population-based cohort studies (such as the Framingham
Heart Study, Rotterdam Study and the Cardiovascular
Health Study) have shown that established vascular factors
(such as hypertension, diabetes mellitus, smoking and
hyperlipidaemias) are risk factors of dementia, including
AD as well as VaD [11]. Additionally, a range of clinical
cardiac diseases are also independent risk factors of
dementia, including atrial fibrillation [12], myocardial
infarction [13] and heart failure [15]. More recently,
markers of subclinical cardiac dysfunction have been
linked to clinical dementia as well as preclinical brain
damage identified on MRI [16].
Taken together, this evidence has formed the basis of
two important research questions that have shaped epi-
demiological research on dementia in recent years. First,
what proportion of the total burden of dementia is, in
fact, caused by vascular risk factors? Second, if vascular
factors are important in dementia, including AD, has im-
proved cardiovascular health in recent decades had an
effect on dementia occurrence?
Several studies have now shown that up to a third of
all dementia cases can be attributed to cardiovascular
risk factors [17–19]. This proportion is not restricted to
VaD cases, but in fact includes all dementia cases, the
majority of which may be due to AD. Importantly, this
indicates that, if cardiovascular risk factors could entirely
be removed from a population, theoretically, a third of
all dementia cases would be preventable. This then leads
to the second question of whether improvement of car-
diovascular risk management has had an effect on de-
mentia occurrence over the last few decades. Already in
2012, the Rotterdam Study presented evidence suggesting
that the incidence of dementia was lower in the period
2000–2005 compared to 1990–1995 [21]; this finding was
subsequently corroborated in several other Western stud-
ies [22–24] and the decrease seems to be attributable to
better cardiovascular prevention. Indeed, a recent lifestyle
intervention randomised controlled trial (RCT) provided,
for the first time, direct evidence of a putative preventive
effect of better cardiovascular control on cognitive decline
Fig. 1 Examples of normal white matter versus severe white matter lesions with and without small vessel disease. Normal white matter and
severe white matter lesions of the parietal deep white matter with and without small vessel disease. A-Ai, normal appearing white matter and a
normal white matter artery (Aii). B, white matter lesion indicated by widespread pallor of the central white matter with typical sparing of the
subcortical U-fibres (arrow); Bi, higher magnification of white matter lesion exhibiting severe rarefaction, i.e., myelin and axonal loss; Bii, white
matter arterioles from white matter lesion area exhibing arteriolosclerosis with hyalinisation (arrows) of vessel walls. C, white matter lesion with
severe white matter pallor; Ci, magnifies image of severe white matter rarefaction; Cii, white matter arteriole with enlarged perivascular space but
no small vessel disease-related fibrosis or hyalinisation. Of note, this case exhibited severe tau pathology in the overlying cortex, suggesting
Wallerian-like degeneration to be the cause for white matter damage. Images captured from serial sections. Histological stain Luxol fast blue was
used for images A, Ai, B, Bi, C and Ci; H&E stain was used for Aii, Bii and Cii. Scale bars represent 1mm in A, B and C and 20μm in Ai, Aii, Bi, Bii,
Ci and Cii
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[25]. If these results are further supported by a number
of on-going non-pharmacological lifestyle intervention
RCTs, there will be important worldwide public health
implications in formulating effective preventive strategies
in the wider population.
Cerebrospinal fluid (CSF) markers
Biomarkers can be measured in a wide range of body
fluids, including blood, urine and saliva, but the CSF has
been studied most extensively in relation to cerebral
nervous system disorders because it often reflects bio-
chemical processes in the brain more accurately compared
to markers in the periphery. Nevertheless, CSF biomarker
studies have been scarce for VCI, compared to AD. Some
biomarker candidates, such as matrix metalloproteinases
[26], have been proposed, but the evidence thus far re-
mains unconvincing.
Because of the significant overlap between AD and
cerebrovascular pathology, the established AD protein
markers total-tau, phosphorylated-tau and amyloid-beta
(Aβ)42 may be promising candidates for VCI/VaD. In a
recently reported evaluation of over 5000 patients with
dementia in Sweden [27], VaD and AD were statistically
assigned to two independent clusters when a combin-
ation of all three AD markers was used for the classifica-
tion. Approximately 15 % of VaD and 60 % of mixed
VaD cases had AD-typical CSF biomarker profiles. Inter-
estingly, over 50 % of VaD cases had low Aβ42 concen-
trations, which may suggest the presence of concomitant
Aβ pathology. The CSF measurements in this study were
performed in clinical practice and might therefore have
influenced the clinical diagnostic process, introducing a
risk of circular reasoning and highlighting the need of
prospective biomarker studies in VCI. Overall, these
findings support the notion that a combined analysis of
the three established AD CSF markers may be most use-
ful in the differential diagnosis of VaD and VCI in more
general terms.
In addition to the search for reliable cerebrovascular
biomarkers, the contribution of cerebrovascular changes
to the pathophysiology of AD and other late-onset de-
mentias are increasingly being recognised [28]. Therefore,
the development and validation of vascular biomarkers
may, indeed, have diagnostic applications in AD and
other dementia types, in addition to VCI. This notion
is highlighted by the two-hit vascular hypothesis of AD
[29], which proposes that microvascular damage may be
the initial insult that leads to the dysfunction of the
blood–brain barrier and/or decreased brain perfusion
resulting in secondary neuronal injury and paving the way
for the accumulation of neurotoxic Aβ oligomers. A leak-
age of neurotoxic proteins into the brain results from
blood–brain barrier disruption, followed by a response
from microglia and astrocytes, angiogenesis, and neuro-
inflammation. These processes can promote white-matter
damage, formation of toxic tau neurofibrillary tangles, loss
of dendritic spines and Aβ accumulation. Despite the
suspected linkage between vascular and AD pathology,
the contribution of vascular changes to AD pathophysi-
ology has not been adequately addressed in most studies
of AD pathophysiology. The majority of biomarker studies
are narrow in scope, investigate only a single category
of brain injury or exclude certain patient groups, e.g.
those with significant vascular risk factors or damage.
In order to successfully develop new improved bio-
markers for VCI and AD, future studies will need to
be more comprehensive, both in terms of the targeted
biomarkers and patient populations.
Neuroimaging of vascular changes
Structural neuroimaging techniques are of pivotal import-
ance for the differential diagnosis of VaD, but also for
elucidating the pathophysiological mechanisms sur-
rounding the development of small vascular lesions in
brain aging. In routine clinical settings, computed tomog-
raphy (CT) and MRI provide evidence of vascular lesions
that are rarely specific of a given diagnostic entity with the
marked exception of cerebral autosomal dominant arterio-
pathy with subcortical infarcts and leucoencephalopathy
(CADASIL). In CADASIL, there are subcortical white
matter lesions affecting the temporal pole and hyperinten-
sity signals on T2-weighted images mainly in pons in the
absence of low intensity T1 signals in deep brain stem and
cerebellum [30].
Besides these rare cases, it is well established that most
clinically overt VCI cases evolve progressively over sev-
eral years via the accumulation of small vascular and
microvascular lesions, mainly in subcortical regions.
Subsequently, the construct of VCI has been proposed
to capture the entire spectrum of cognitive disorders asso-
ciated with all forms of cerebral vascular brain injury, not
solely stroke, ranging from mild cognitive impairment
through to fully developed dementia. As already proposed
by the NINDS-AIREN criteria and subsequently confirmed
by neuroimaging studies, a substantial percentage of VaD
cases is due to SVD affecting small cerebral arterioles,
capillaries and venules possibly due to intrinsic arteriolar
occlusive disorder [31]. Although the small vessels are not
easily identifiable, detailed neuroimaging may allow for
tracking of their pathology in the human brain. The main
imaging features of SVD visible on 1.5 T and 3 T MRI
scans are acute lacunar infarcts, neurologically silent
lacunes, white matter hyperintensities, increased perivascu-
lar spaces and microbleeds [32, 33] (Figs. 2 and 3). Micro-
infarcts are strongly related to cognitive decline, yet they
are detectable only at higher field strengths, usually only
available in research facilities [34]. Lacunar strokes corres-
pond to lesions less than 20 mm in axial diameter; old
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lacunes are small cavities between 3 and 15 mm in diam-
eter located in the deep grey or white matter [27]. Both
these lesions are known to affect cognition, mainly in pure
VaD cases [35]. On MRI scans, they are detected by in-
creased signal on diffusion-weighted imaging, reduced sig-
nal on an apparent diffusion coefficient map, increased
signal on fluid-attenuated inversion recovery, increased
T2-weighted imaging, reduced signal on T1-weighted
MRI, and low attenuation on CT scanning. White matter
hyperintensities are areas of decreased attenuation in CT
scans, increased signal on T2 and fluid-attenuated inver-
sion recovery sequences, and in some cases decreased on
T1-weighted MRI scans. Present in periventricular and
deep white matter, in the basal ganglia (deep grey matter)
and more rarely in pons and cerebellum, they signal the
progression of SVD and their severity is related to the
emergence of VaD in clinical samples [36]. Increased peri-
vascular spaces are visible on T2- and T1-weighted MRI
scans mostly in basal ganglia and subcortical white matter.
Strongly related to white matter hyperintensities, they
are very frequent in old age but the increase of their
number is related to VCI [37]. Finally, cortical micro-
bleeds are punctiform areas of hypointensity on T2-
or susceptibility-weighted sequences, of up to 1 cm of
diameter. An impressive number of studies have attempted
to define their cognitive significance with conflicting results
[38–40]; their negative impact on cognition is highly likely
in VaD, but much less in mixed cases.
In addition to microvascular and small macrovascular
lesions, recent contributions pointed to the presence of
white matter microstructure changes assessed with diffu-
sion tensor imaging (DTI) at the early stages of cognitive
decline (reviewed in [41]). Several DTI-derived parameters
were taken into account, including fractional anisotropy
and longitudinal, radial and mean diffusivity. Tract-based
spatial statistics were used to project DTI-derived data
onto a mean tract skeleton by using non-linear registration.
The tract skeleton is the basis for voxel-wise cross-subject
statistics and reduces potential misregistrations as the
source for false-positive or false-negative analysis results.
Applying voxel-wise DTI analyses, a significant decrease of
fractional anisotropy values was detected in hemispheric
deep white matter and corpus callosum in patients with
VCI compared to healthy controls [42]. Although still in its
infancy, the automatic processing of DTI data at an indi-
vidual level using support vector machine analysis may
allow identification of the very first signs of biological com-
promise of white matter in VCI.
Fig. 2 Examples of typical brain magnetic resonance imaging changes associated with vascular cognitive impairment. A Hypertensive cerebral
microbleeds. Typical appearance of hypertensive cerebral microbleeds in patients around 70 years of age. Note the random distribution including
supratentorial superficial white matter (Ai), intraparenchymal (Aii), and infratentorial region (Aiii). B Cerebral amyliod angiopathy. Typical manifestaion
of celebral amyloid angiopathy in a 72 years old patient, including multiple microbleeds with a labor distribution sparing the deep grey matter and
infratentorial region (Bi), superficial siderosis of the covexity (Bii) and periventricular leucoencephalopathy (Biii)
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Familial forms of vascular dementia
Herein, we briefly summarise the available data in rela-
tion to clinical diagnostic criteria. The genetic underpin-
ning of cerebrovascular changes has been less well
studied compared to other dementia forms, such as AD
[43]. However, in most genetic studies in sporadic AD,
the inclusion criteria are such that they may allow a vari-
able number of cases and/or of mixed pathologies to be
included. Of note, the upper age limit of most of these
studies is in excess of 80 years, when mixed pathologies
are common. Thus far, studies have failed to characterise
the heritability of sporadic VCI but there have been several
reports on rare monogenic conditions involving cerebral
small vessels and predisposing to ischemic and/or haemor-
rhagic stroke and diffuse white matter disease. In these dis-
orders, the primary genetic defect (autosomal dominant,
recessive or X linked) may alter endothelial cells of micro-
vessels leading to impairment of deep brain vascularisation
and resulting in clinical manifestations such as subcortical
leucoencephalopathy and episodes of stroke.
A diagnosis of hereditary cerebral small vessel disease
has to be considered in familial cerebrovascular disorders
occurring mainly in young adulthood; it can be distin-
guished from sporadic cerebral microangiopathy due to
the presence of a high vascular risk load. The most im-
portant clinical entities are CADASIL, cerebral autosomal
recessive arteriopathy with subcortical infarcts and leu-
coencephalopathy, COL4A1-related cerebral small vessel
diseases, autosomal dominant retinal vasculopathy with
cerebral leuco-dystrophy, and Fabry disease. The main
clinical and genetic characteristics of these disorders are
presented in Table 1. Although they have variable pheno-
types and different defective genes, all these diseases cause
arteriopathy and microvascular disintegration leading to
VCI. In these cases, genetic, biochemical or pathological
analyses will confirm the clinical suspicion and are very
useful in clinical practice (Table 2) [4, 44, 45]. Specific
substitution treatment with recombinant enzymes is
available only for Fabry’s disease, and treatment mainly
improves non-central nervous system organ function
(kidney, heart, peripheral nerve, etc.), with little change in
central neurological abnormalities because of the difficulty
of the enzyme to cross the blood–brain barrier [46].
Recommendations and future perspectives
Despite significant progress in recent years, important
gaps in knowledge persist in terms of the extent and
granularity of dementia types and their distinct under-
lying biological pathways, as well as the mechanisms
underpinning cognitive deterioration. There is abundant
evidence that mixed pathologies are very prevalent in
patients over the age of 75 and that pure VCI is rare. It
is also evident that cognitive profiles may differ between
different types of dementia and that the AD-centred
definition of dementia may not be appropriate for other
dementia types. We have also learned, from large-scale
Fig. 3 Examples of typical magnetic resonance imaging of white matter disease. White matter lesions. Usually attributed to chronic small vessel
ischaemia, rating using the Fazekas scale. No lesions or single punctate lesion (grade 0), multiple punctate lesions (grade 1), beginning confluency
of lesions (bridging, grade 2), large confluent lesions (grade 3)
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clinical trials, that AD-specific treatments, such as cholin-
esterase inhibitors and memantine, may not show the
desired effects in people with other dementias. Imaging
and fluid biomarkers are useful in differentiating AD from
VCI and to enrich trial populations with relatively pure
cases. However, significant pathological (and presumably
nosological) overlaps do exist between the diagnostic
groups, even in biomarker-based clinically diagnosed
cases, whereas biomarkers are still not part of the diagnos-
tic armamentarium in the majority of clinical dementia
settings worldwide.
In view of these significant gaps of knowledge, further
research is urgently required to address key issues. Firstly,
our understanding of the key pathogenic mechanisms of
VCI is far less developed than for AD. They include not
only the determinants of vascular burden in the human
brain but also its indirect consequences (increased
neuro-inflammation, altered oxidative stress regulation,
changes in brain reactivity) over time. Further, shared
patho-mechanisms between VCI and AD remain poorly
understood in view of their complexity. Secondly, large
population-based studies have identified important risk
factors for late-life dementia and some are, indeed,
modifiable, thus promising targets for prevention and
treatment strategies. This important hypothesis now
needs to be scrutinised in appropriately powered prospect-
ive pharmacological and non-pharmacological RCTs.
Thirdly, fragmented research initiatives must be brought
together in coordinated international research programs
in order to optimally utilise human, financial and other re-
sources and increase power. For example, large-scale pro-
spective longitudinal studies aimed at identifying genetic
and other risk factors may also identify predictive and
diagnostic markers. The accumulated information may
well allow for a better delineation and definition of de-
mentia types, such as AD and VCI and, potentially, their
subtypes. We have learned from other disease areas, such
as cancer, that this is a pre-condition for the discovery and
Table 1 Characteristics of important inherited cerebral small vessel diseases
Disease Gene Protein Onset age Clinical features
CADASIL NOTCH3
(autosomal dominant)
Notch3 receptor protein 30–40 years Progressive dementia, mood disorders, migraine,
recurrent subcortical cerebral, infarction On MRI,
leucoencephalopathy, mainly in temporal poles
CARASIL HTRA1
(autosomal recessive)
HTRA1, serine protease 20–30 years Mood changes, pseudobulbar palsy, mental dysfunction,
scalp alopecia in the teen, acute mid-to-lower back pain
Subcortical white matter changes on MRI
Heterozygous autosomal dominant form: later age of
onset and absence of typical extraneurological features
COL4A1 COL4A1
(autosomal dominant)
Type IV collagen α1-chain All ages Ischemic stroke, intracerebral haemorrhage, retinal
arteriolar tortuosity, cataracts, glaucoma, anterior segment
dysgenesis of the eye (Axenfeld–Rieger anomaly),
muscle cramps, Raynaud phenomena, kidney defects
RVCL TREX1
(autosomal dominant)
Trex1 DNAse III 30–40 years Retinal vasculopathy, TIA, strokes, cognitive dysfunction,
headaches, personality disorders, Raynaud’s phenomena,
liver and kidney dysfunction
Fabry disease alpha-GalA
(X-linked)
Alpha-galactosidase (α-GalA) Childhood Classic form: acroparesthesias, angiokeratomas, hypohidrosis,
characteristic corneal and lenticular opacities, proteinuria,
peripheral neuropathy, TIA and stroke, heart disturbances
and cardiomyopathy Heterozygous females: milder symptoms,
later onset
CADASIL cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy, CARASIL cerebral autosomal recessive arteriopathy with
subcortical infarcts and leucoencephalopathy, COL4A1 COL4A1-associated diseases, RVCL retinal vasculopathy with cerebral leucodystrophy, TIA transient
ischemic attack
Table 2 In vivo diagnosis of genetic small vessel diseases
Disease Genetic investigations Pathological investigations Biochemical investigations
CADASIL NOTCH3 mutations Evidence of granular osmiophilic
material in affected arterioles
None
CARASIL HTRA1 mutations N/A N/A
COL4A1 COL4A1 type IV collagen α1-chain N/A N/A
RVCL TREX1 DNAse III N/A N/A
Fabry disease Alpha Gal-A gene mutations Lysosomal abnormalities in tissues Deficiency a-galactosidase activity in serum, urine, leucocytes,
tissues; abnormalities in urinary and tissues glycolipids
CADASIL cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy, CARASIL cerebral autosomal recessive arteriopathy with
subcortical infarcts and leucoencephalopathy, COL4A1 COL4A1-associated diseases, RVCL retinal vasculopathy with cerebral leucodystrophy
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development of effective new medicines. Finally, the pre-
dementia and pre-clinical stages of VCI have to be defined
more precisely and we propose that the term vascular
mild cognitive impairment is used in line with the concept
of mild cognitive impairment due to AD to characterise
the early clinical stage that precedes VaD.
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